Nahum Puebla-Osorio, D.V.M., Ph.D.

Peer-Reviewed Articles

1. He K, Hong DS, Ke D, Kebriaei P, Wang T, Danesi H, Bertolet G, Leuschner C, Puebla-Osorio N, Voss TA, Lin Q, Norry E, Fracasso PM, Welsh JW. Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report. Melanoma Res 33(4):332-337, 2023. e-Pub 2023. PMID: 37325860.
2. Hu Y, Paris S, Sahoo N, Bertolet G, Wang Q, Wang Q, Barsoumian HB, Da Silva J, Huang A, Doss DJ, Pollock DP, Hsu E, Selene N, Leyton CSK, Voss TA, Masrorpour F, Ganjoo S, Leuschner C, Pietz JT, Puebla-Osorio N, Gandhi S, Nguyen QN, Wang J, Cortez MA, Welsh JW. Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection. JCI Insight 8(12), 2023. e-Pub 2023. PMID: 37345658.
3. Jallouk AP, Gouni S, Westin J, Feng L, Mistry H, Steiner RE, James J, Noorani M, Horowitz S, Puebla-Osorio N, Fayad LE, Iyer SP, Hawkins M, Flowers CR, Ahmed S, Nastoupil LJ, Kebriaei P, Shpall EJ, Neelapu SS, Nieto Y, Strati P. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response. Haematologica 108(4):1163-1167, 2023. e-Pub 2023. PMID: 36384251.
4. He K, Barsoumian HB, Puebla-Osorio N, Hu Y, Sezen D, Wasley MD, Bertolet G, Zhang J, Leuschner C, Yang L, Kettlun Leyton CS, Fowlkes NW, Green MM, Hettrick L, Chen D, Masrorpour F, Gu M, Maazi H, Revenko AS, Cortez MA, Welsh JW. Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD-1 in Metastatic Non-Small Cell Lung Cancer. Cancer Immunol Res 11(4):486-500, 2023. PMID: 36700864.
5. Hu Y, Paris S, Bertolet G, Barsoumian HB, He K, Sezen D, Chen D, Wasley M, Silva JD, Mitchell JA, Voss TA, Masrorpour F, Leyton CK, Yang L, Leuschner C, Puebla-Osorio N, Gandhi S, Nguyen QN, Cortez MA, Welsh JW. Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer. J Nanobiotechnology 20(1):417, 2022. e-Pub 2022. PMID: 36123677.
6. Barsoumian HB, Sezen D, Menon H, Younes AI, Hu Y, He K, Puebla-Osorio N, Wasley M, Hsu E, Patel RR, Yang L, Cortez MA, Welsh JW. High Plus Low Dose Radiation Strategy in Combination with TIGIT and PD1 Blockade to Promote Systemic Antitumor Responses. Cancers (Basel) 14(1), 2022. e-Pub 2022. PMID: 35008385.
7. Sezen D, Barsoumian HB, He K, Hu Y, Wang Q, Abana CO, Puebla-Osorio N, Hsu EY, Wasley M, Masrorpour F, Wang J, Cortez MA, Welsh JW. Pulsed radiotherapy to mitigate high tumor burden and generate immune memory. Front Immunol 13:984318, 2022. e-Pub 2022. PMID: 36275767.
8. Ganjoo S, Puebla-Osorio N, Nanez S, Hsu E, Voss T, Barsoumian H, Duong LK, Welsh JW, Cortez MA. Bone morphogenetic proteins, activins, and growth and differentiation factors in tumor immunology and immunotherapy resistance. Front Immunol 13:1033642, 2022. e-Pub 2022. PMID: 36353620.
9. Hu Y, Paris S, Bertolet G, Barsoumian HB, Wang Q, Da Silva J, Patel NB, Nguyen N, Doss DJ, Huang A, Hsu E, Leyton CSK, Voss TA, Masrorpour F, Leuschner C, Pietz JT, Puebla-Osorio N, Gandhi S, Nguyen QN, Wang J, Cortez MA, Welsh JW. NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model. Front Immunol 13:1022011, 2022. e-Pub 2022. PMID: 36405757.
10. Kewen He 1 2 3, Hampartsoum B Barsoumian 3, Genevieve Bertolet 3, Vivek Verma 4, Carola Leuschner 3, Eugene J Koay 5, Ethan B Ludmir 6, Ethan Hsu 3, Esha Pisipati 3, Tiffany A Voss 3, Nahum Puebla-Osorio 3, Maria Angelica Cortez 3, James W Welsh 3. Novel Use of Low-Dose Radiotherapy to Modulate the Tumor Microenvironment of Liver Metastases. Front Immunol 12:812210, 2021.
11. Kewen He 1 2, Hampartsoum B Barsoumian 1, Duygu Sezen 1 3, Nahum Puebla-Osorio 1, Ethan Y Hsu 1, Vivek Verma 4, Chike O Abana 1, Dawei Chen 2, Roshal R Patel 5, Meidi Gu 6, Maria Angelica Cortez 1, James W Welsh 1. Pulsed Radiation Therapy to Improve Systemic Control of Metastatic Cancer. Front Oncol 11:737425, 2021.
12. Sezen D, Verma V, He K, Abana CO, Barsoumian H, Ning MS, Tang C, Hurmuz P, Puebla-Osorio N, Chen D, Tendler I, Comeaux N, Nguyen QN, Chang JY, Welsh JW. Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease. Semin Radiat Oncol 31(3):217-226, 2021. PMID: 34090648.
13. Mueller-Schoell A, Puebla-Osorio N, Michelet R, Green MR, Künkele A, Huisinga W, Strati P, Chasen B, Neelapu SS, Yee C, Kloft C. Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model. Cancers (Basel) 13(11), 2021. e-Pub 2021. PMID: 34205020.
14. Patel RR, Verma V, Barsoumian HB, Ning MS, Chun SG, Tang C, Chang JY, Lee PP, Gandhi S, Balter P, Dunn JD, Chen D, Puebla-Osorio N, Cortez MA, Welsh JW. Use of Multi-Site Radiation Therapy for Systemic Disease Control. Int J Radiat Oncol Biol Phys 109(2):352-364, 2021. e-Pub 2020. PMID: 32798606.
15. Younes AI, Barsoumian HB, Sezen D, Verma V, Patel R, Wasley M, Hu Y, Dunn JD, He K, Chen D, Menon H, Masrorpour F, Gu M, Yang L, Puebla-Osorio N, Cortez MA, Welsh JW. Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity. Transl Oncol 14(2):100983, 2021. e-Pub 2020. PMID: 33340886.
16. Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, Dai E, Dang M, Jain N, Yang H, Wang Y, Zhang S, Wang R, Chen R, Showell J, Ghosh S, Patchva S, Zhang Q, Sun R, Hagemeister F, Fayad L, Samaniego F, Lee HC, Nastoupil LJ, Fowler N, Eric Davis R, Westin J, Neelapu SS, Wang L, Green MR. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med 26(12):1878-1887, 2020. e-Pub 2020. PMID: 33020644.
17. Harden, A., Puebla-Osorio, N..., and Schadler K.. Modifiers of Endothelial Permeability in the Setting of CAR-t Therapy Related Immune Cell Associated Neurotoxicity Syndrome. Biology of Blood and Marrow Transplantation 26(3):258, 2020.
18. Soria-Castro R, Schcolnik-Cabrera A, Rodríguez-López G, Campillo-Navarro M, Puebla-Osorio N, Estrada-Parra S, Estrada-García I, Chacón-Salinas R, Chávez-Blanco AD. Exploring the drug repurposing versatility of valproic acid as a multifunctional regulator of innate and adaptive immune cells. J Immunol Res 9678098:9678098, 2019. e-Pub 2019. PMID: 31001564.
19. Zhang H, Li HS, Hillmer EJ, Zhao Y, Chrisikos TT, Hu H, Wu X, Thompson EJ, Clise-Dwyer K, Millerchip KA, Wei Y, Puebla-Osorio N, Kaushik S, Santos MA, Wang B, Garcia-Manero G, Wang J, Sun SC, Watowich SS. Genetic rescue of lineage-balanced blood cell production reveals a crucial role for STAT3 anti-inflammatory activity in hematopoiesis. Proc Natl Acad Sci U S A 115(10):E2311-E2319, 2018. e-Pub 2018. PMID: 29463696.
20. Campillo-Navarro M, Leyva-Paredes K, Donis-Maturano L, Rodríguez-López GM, Soria-Castro R, García-Pérez BE, Puebla-Osorio N, Ullrich SE, Luna-Herrera J, Flores-Romo L, Sumano-López H, Pérez-Tapia SM, Estrada-Parra S, Estrada-García I, Chacón-Salinas R. Mycobacterium tuberculosis Catalase Inhibits the Formation of Mast Cell Extracellular Traps. Front Immunol 9:1161, 2018. e-Pub 2018. PMID: 29892297.
21. Damiani E, Puebla-Osorio N, Lege BM, Liu J, Neelapu SS, Ullrich SE. Platelet activating factor up-regulates p21 expression in human mast cells via histone acetylation. Sci Rep 7:41959, 2017. e-Pub 2017. PMID: 28157211.
22. Puebla-Osorio N, Sarchio SNE, Ullrich SE, Byrne SN. Detection of Infiltrating Mast Cells Using a Modified Toluidine Blue Staining. Methods Mol Biol 1627:213-222, 2017. PMID: 28836204.
23. Damiani E, Puebla-Osorio N, Gorbea E, Ullrich SE. Platelet-Activating Factor Induces Epigenetic Modifications in Human Mast Cells. J Invest Dermatol 135(12):3034-40, 2015. e-Pub 2015. PMID: 26316070.
24. Puebla-Osorio N, Damiani E, Bover L, Ullrich SE. Platelet-activating factor induces cell cycle arrest and disrupts the DNA damage response in mast cells. Cell Death Dis 6:e1745, 2015. e-Pub 2015. PMID: 25950475.
25. Sun M, Zhou C, Zeng H, Puebla-Osorio N, Damiani E, Chen J, Wang H, Li G, Yin F, Shan L, Zuo D, Liao Y, Wang Z, Zheng L, Hua Y, Cai Z. Hiporfin-mediated photodynamic therapy in preclinical treatment of osteosarcoma. Photochem Photobiol 91(3):e1745. doi: 10.1038/cddis.2015.115, 2015. e-Pub 2015. PMID: 25619546.
26. Puebla-Osorio N, Kim J, Ojeda S, Zhang H, Tavana O, Li S, Wang Y, Ma Q, Schluns KS, Zhu C. A novel Ku70 function in colorectal homoeostasis separating from nonhomologous end joining. Oncogene 33(21):2748-57, 2014. e-Pub 2013. PMID: 23752193.
27. Chang JH, Hu H, Jin J, Puebla-Osorio N, Xiao Y, Gilbert BE, Brink R, Ullrich SE, Sun SC. TRAF3 regulates the effector function of regulatory T cells and humoral immune responses. J Exp Med 211(1):137-51, 2014. e-Pub 2013. PMID: 24378539.
28. Tavana O, Puebla-Osorio N, Kim J, Sang M, Jang S, Zhu C. Ku70 functions in addition to nonhomologous end joining in pancreatic β-cells: a connection to β-catenin regulation. Diabetes 62(7):2429-38, 2013. e-Pub 2013. PMID: 23474484.
29. Hu H, Brittain GC, Chang JH, Puebla-Osorio N, Jin J, Zal A, Xiao Y, Cheng X, Chang M, Fu YX, Zal T, Zhu C, Sun SC. OTUD7B controls non-canonical NF-κB activation through deubiquitination of TRAF3. Nature 494(7437):371-4, 2013. e-Pub 2013. PMID: 23334419.
30. Puebla-Osorio N, Miyahara Y, Coimbatore S, Limón-Flores AY, Kazimi N, Ullrich SE, Zhu C. Induction of B-cell lymphoma by UVB radiation in p53 haploinsufficient mice. BMC Cancer 11:36, 2011. e-Pub 2011. PMID: 21269511.
31. Tavana O, Benjamin CL, Puebla-Osorio N, Sang M, Ullrich SE, Ananthaswamy HN, Zhu C. Absence of p53-dependent apoptosis leads to UV radiation hypersensitivity, enhanced immunosuppression and cellular senescence. Cell Cycle 9(16):3328-36, 2010. e-Pub 2010. PMID: 20703098.
32. Dujka ME, Puebla-Osorio N, Tavana O, Sang M, Zhu C. ATM and p53 are essential in the cell-cycle containment of DNA breaks during V(D)J recombination in vivo. Oncogene 29(7):957-65, 2010. e-Pub 2009. PMID: 19915617.
33. Tavana O, Puebla-Osorio N, Sang M, Zhu C. Absence of p53-dependent apoptosis combined with nonhomologous end-joining deficiency leads to a severe diabetic phenotype in mice. Diabetes 59(1):135-42, 2010. e-Pub 2009. PMID: 19833883.
34. Puebla-Osorio N, Zhu C. DNA damage and repair during lymphoid development: antigen receptor diversity, genomic integrity and lymphomagenesis. Immunol Res 41(2):103-22, 2008. PMID: 18214391.
35. Van Nguyen T, Puebla-Osorio N, Pang H, Dujka ME, Zhu C. DNA damage-induced cellular senescence is sufficient to suppress tumorigenesis: a mouse model. J Exp Med 204(6):1453-61, 2007. e-Pub 2007. PMID: 17535972.
36. Puebla-Osorio N, Lacey DB, Alt FW, Zhu C. Early embryonic lethality due to targeted inactivation of DNA ligase III. Mol Cell Biol 26(10):3935-41, 2006. PMID: 16648486.
37. Kingsley RA, Abi Ghanem D, Puebla-Osorio N, Keestra AM, Berghman L, Bäumler AJ. Fibronectin binding to the Salmonella enterica serotype Typhimurium ShdA autotransporter protein is inhibited by a monoclonal antibody recognizing the A3 repeat. J Bacteriol 186(15):4931-9, 2004. PMID: 15262930.
38. Puebla-Osorio N, Ramos KS, Falahatpisheh MH, Smith R, Berghman LR. 2,3,7,8-Tetrachlorodibenzo-p-dioxin elicits aryl hydrocarbon receptor-mediated apoptosis in the avian DT40 pre-B-cell line through activation of caspases 9 and 3. Comp Biochem Physiol C Toxicol Pharmacol 138(4):461-8, 2004. PMID: 15536054.
39. Puebla-Osorio N, Proudman JA, Compton AE, Clements KE, Decuypere E, Vandesande F, Berghman LR. FSH- and LH-cells originate as separate cell populations and at different embryonic stages in the chicken embryo. Gen Comp Endocrinol 127(3):242-8, 2002. PMID: 12225765.
40. Berghman, L.R., D’Hondt, E., Puebla, N., Dees, L., Hiney, J., Sower, S., and Vandesande, F.. Immunocytochemical evidence for the existence of a lamprey luteinizing hormone-releasing hormone type III-like peptide in the chicken hypothalamus. British Poult. Sci 41(1):56-57, 2000.

Book Chapters

1. Puebla-Osorio, N. Strati, P, and Neelapu S.. The tumor microenvironment in follicular lymphoma. In: Follicular Lymphoma. Springer Cham: Switzerland, 65-82, 2020.
2. Nahum Puebla-Osorio1, Seri N.E. Sarchio2,3, Stephen E. Ullrich4, Scott N. Byrne2. Chapter 14: Detection of infiltrating mast cells using a modified toluidine blue staining. In: Methods in Molecular Biology. Springer: New York, 213-222, 2017.